SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): January
6, 2022
AXIM BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Nevada
|
|
000-54296
|
|
27-4092986
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
6191 Cornerstone Court, E., Suite 114
San Diego, California
|
|
92121
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(858)
923-4422
(Registrant’s telephone number, including area code)
(Former name if changed since last report)
|
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the
following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
5.02Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements with Certain Officers
Appointment of Blake N. Schroeder as Director
On January 6, 2022, the record holder of 500,000 shares of AXIM
Biotechnologies, Inc. (the “Company”) Series C Preferred Stock,
representing 100% of the 500,000 shares of Series C Preferred Stock
issued and outstanding, which shares are entitled to cast a vote
for election of up to four (4) Series C Directors, whether by
shareholder meeting (annual or special) or by written consent,
acting pursuant to Section 78.320 of the Nevada Revised Statutes
and Article III, Section 3 of the Company’s Amended and Restated
Bylaws, consented by written consent in lieu of a meeting
appointing Blake N. Schroeder to fill the director seat vacated by
the resignation of Mauricio Javier Gatto-Bellora.
Mr. Blake N. Schroeder, 42, began his career with a commercial
litigation law firm in Salt Lake City, Utah. Beginning in 2008,
Schroeder focused on the sale and marketing of natural products and
opening international marketplaces to those products. From 2008 to
2014 Mr. Schroeder served in various capacities at MonaVie, LLC
developing international business plans and growing international
businesses. From August 2014 to February 2016, Mr. Schroeder
served as the Chief Operating Officer of Forevergreen
International, where he was responsible for global operation and
sales of the multinational organization, including oversight of a
global supply chain. From 2021 to the present, Mr. Schroeder
has served as the Chief Executive Officer and Chairman of the Board
of Medical Marijuana, Inc. From 2016 to the present, Mr.
Schroeder serves as the chief executive officer of Kannaway USA,
LLC, a wholly owned subsidiary of Medical Marijuana, Inc.
Medical Marijuana, Inc. is one of the Company’s largest
shareholders holding approximately 16.4% of the Company’s common
stock, as of January 10, 2022. Mr. Schroeder holds a B.S. in
Finance from Utah State University and a law degree from Syracuse
University College of Law.
There are no arrangements or understandings between Mr. Schroeder
and any other person pursuant to which Mr. Schroeder was appointed
as a director of the Company. Mr. Schroeder is not a participant
in, nor is he to be a participant in, any related-person
transaction or proposed related-person transaction required to be
disclosed by Item 404(a) of Regulation S-K under the Securities
Exchange Act of 1934, as amended. There are no familial
relationships between Mr. Schroeder and any of the Company’s
directors, executive officers or persons nominated or chosen by the
Company to become a director or executive officer.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
AXIM
BIOTECHNOLOGIES, INC.
|
Dated: January 11,
2022
|
By:
|
/s/ John W.
Huemoeller II
|
|
|
Name: John W.
Huemoeller II
|
|
|
Chief Executive
Officer
|